AlloVir (ALVR) Competitors $9.01 -0.20 (-2.17%) As of 03/27/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALVR vs. CKPT, FDMT, NMRA, CRGX, CGC, CTNM, KOD, PLX, GNFT, and ADCTShould you be buying AlloVir stock or one of its competitors? The main competitors of AlloVir include Checkpoint Therapeutics (CKPT), 4D Molecular Therapeutics (FDMT), Neumora Therapeutics (NMRA), CARGO Therapeutics (CRGX), Canopy Growth (CGC), Contineum Therapeutics (CTNM), Kodiak Sciences (KOD), Protalix BioTherapeutics (PLX), Genfit (GNFT), and ADC Therapeutics (ADCT). These companies are all part of the "pharmaceutical products" industry. AlloVir vs. Checkpoint Therapeutics 4D Molecular Therapeutics Neumora Therapeutics CARGO Therapeutics Canopy Growth Contineum Therapeutics Kodiak Sciences Protalix BioTherapeutics Genfit ADC Therapeutics Checkpoint Therapeutics (NASDAQ:CKPT) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, community ranking, earnings, profitability and analyst recommendations. Which has more volatility & risk, CKPT or ALVR? Checkpoint Therapeutics has a beta of 1.41, indicating that its stock price is 41% more volatile than the S&P 500. Comparatively, AlloVir has a beta of 0.63, indicating that its stock price is 37% less volatile than the S&P 500. Does the MarketBeat Community favor CKPT or ALVR? Checkpoint Therapeutics received 154 more outperform votes than AlloVir when rated by MarketBeat users. Likewise, 67.04% of users gave Checkpoint Therapeutics an outperform vote while only 57.45% of users gave AlloVir an outperform vote. CompanyUnderperformOutperformCheckpoint TherapeuticsOutperform Votes18167.04% Underperform Votes8932.96% AlloVirOutperform Votes2757.45% Underperform Votes2042.55% Do institutionals and insiders believe in CKPT or ALVR? 22.0% of Checkpoint Therapeutics shares are owned by institutional investors. Comparatively, 66.1% of AlloVir shares are owned by institutional investors. 2.1% of Checkpoint Therapeutics shares are owned by insiders. Comparatively, 32.1% of AlloVir shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has higher earnings and valuation, CKPT or ALVR? Checkpoint Therapeutics has higher revenue and earnings than AlloVir. Checkpoint Therapeutics is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCheckpoint Therapeutics$47K4,192.37-$51.85M-$1.84-2.19AlloVirN/AN/A-$190.42M-$20.23-0.46 Is CKPT or ALVR more profitable? Checkpoint Therapeutics' return on equity of 0.00% beat AlloVir's return on equity.Company Net Margins Return on Equity Return on Assets Checkpoint TherapeuticsN/A N/A -659.07% AlloVir N/A -71.03%-61.27% Do analysts recommend CKPT or ALVR? Checkpoint Therapeutics presently has a consensus target price of $4.33, suggesting a potential upside of 7.39%. Given Checkpoint Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Checkpoint Therapeutics is more favorable than AlloVir.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Checkpoint Therapeutics 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media prefer CKPT or ALVR? In the previous week, Checkpoint Therapeutics had 1 more articles in the media than AlloVir. MarketBeat recorded 4 mentions for Checkpoint Therapeutics and 3 mentions for AlloVir. Checkpoint Therapeutics' average media sentiment score of 0.96 beat AlloVir's score of 0.43 indicating that Checkpoint Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Checkpoint Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AlloVir 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryCheckpoint Therapeutics beats AlloVir on 12 of the 16 factors compared between the two stocks. Remove Ads Get AlloVir News Delivered to You Automatically Sign up to receive the latest news and ratings for ALVR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALVR vs. The Competition Export to ExcelMetricAlloVirBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$46.45M$3.02B$5.63B$7.89BDividend YieldN/A1.56%4.57%4.01%P/E Ratio-0.4628.9123.1218.72Price / SalesN/A426.13384.2791.12Price / CashN/A168.6838.1634.64Price / Book0.313.866.884.24Net Income-$190.42M-$71.95M$3.20B$247.06M7 Day Performance-19.21%-5.26%-2.57%-1.72%1 Month Performance-6.02%-11.75%1.95%-5.34%1 Year Performance-46.96%-28.26%9.80%-0.38% AlloVir Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALVRAlloVir2.2097 of 5 stars$9.01-2.2%N/A-47.4%$45.44MN/A-0.45110Gap UpCKPTCheckpoint Therapeutics2.4737 of 5 stars$3.99+0.5%$4.33+8.6%+97.5%$194.84M$47,000.00-2.1710Short Interest ↓High Trading VolumeFDMT4D Molecular Therapeutics2.8367 of 5 stars$4.18+1.7%$30.63+632.7%-90.1%$193.54M$37,000.00-1.47120NMRANeumora Therapeutics3.2271 of 5 stars$1.19-7.0%$10.14+752.3%-91.3%$192.76MN/A-0.64108High Trading VolumeCRGXCARGO Therapeutics2.9375 of 5 stars$4.11-2.4%$15.00+265.0%-81.4%$189.27MN/A-0.96116Analyst RevisionGap UpCGCCanopy Growth2.4277 of 5 stars$1.18+7.3%$2.00+69.5%-89.0%$187.17M$276.75M-0.313,150Positive NewsCTNMContineum Therapeutics2.165 of 5 stars$7.06+5.8%$24.80+251.3%N/A$181.99M$50M-1.4431KODKodiak Sciences4.0414 of 5 stars$3.45-5.2%$8.00+131.9%-58.9%$181.55MN/A-0.9590Earnings ReportUpcoming EarningsNews CoverageGap DownPLXProtalix BioTherapeutics2.2219 of 5 stars$2.45+9.4%$15.00+512.2%+107.2%$180.40M$45.67M-18.85200Gap UpHigh Trading VolumeGNFTGenfit2.1213 of 5 stars$3.58+1.9%$13.00+263.5%+0.9%$178.79M$76.06M0.00120Upcoming EarningsGap UpADCTADC Therapeutics2.1809 of 5 stars$1.79-3.5%$8.50+376.2%-64.4%$172.59M$70.72M-0.75310Earnings ReportShort Interest ↓News CoverageGap Down Remove Ads Related Companies and Tools Related Companies CKPT Alternatives FDMT Alternatives NMRA Alternatives CRGX Alternatives CGC Alternatives CTNM Alternatives KOD Alternatives PLX Alternatives GNFT Alternatives ADCT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALVR) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredTrump’s Treasure Map [Pic inside]We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men...Paradigm Press | SponsoredDoomed: These 50 Stocks Will Die Under Trump’s MAGA policies.Remember Kodak? Sears? Circuit City? They all failed to adapt to the changing times. Now, history is abo...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AlloVir, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AlloVir With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
